ARTICLE | Clinical News
Cebix preclinical data
July 4, 2011 7:00 AM UTC
In a rat model of diabetic peripheral neuropathy, subcutaneous Ersatta led to a 4 m/sec reversal of sensory nerve conduction velocity impairment. The long-acting form of C-peptide is in Phase Ib testi...